Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Otsuka Pharmaceutical Co. Ltd.
BioCentury | Oct 22, 2024
Product Development
Otsuka to take advantage of newly charted accelerated pathway for IgA nephropathy
BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more
BioCentury | Sep 6, 2024
Distillery Therapeutics
Inhibiting CDA for checkpoint inhibitor-resistant cancers
BioCentury | Aug 6, 2024
Deals
Deals Report: Bispecific space continues to foster partnerships
Plus: Otsuka in $800M takeout of Jnana, BioNTech dropping Genmab’s acasunlimab
BioCentury | Aug 1, 2024
Deals
Platform, PKU asset drive Otsuka’s $800M takeout of Jnana
As lead program nears pivotal trial, Japanese pharma adds subsidiary to build U.S. discovery capabilities; deal gives strong exit to VC syndicate
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | Jan 22, 2024
Product Development
Clinical roundup: new data from Gilead, Sagimet, Ionis, Novartis and BMS
Gilead falls on Trodelvy readout; plus Sagimet’s value-driving NASH data, and updates from Ionis, Novartis and BMS
BioCentury | Dec 20, 2023
Deals
Dec. 19 Quick Takes: Ionis, Otsuka in European deal for HAE therapy
Plus: Carmot spinout Kimia raises $55M series A round, CureVac tumbles on loss in patent case and more from Lassen, Atavistik, Crinetics, Merck and CSL
BioCentury | Oct 27, 2023
Politics, Policy & Law
Oct. 27 Quick Takes: AbbVie pegs IRA cost at $2.1 billion
Plus: FDA approves Coherus’ PD-1 mAb based on China data, and updates from Otsuka, Sernova, Lilly, Roche and more
BioCentury | Sep 25, 2023
Management Tracks
Remy Sukhija leaving Madrigal as CCO
Plus: Editas hires Caren Deardorf as chief commercial and strategy officer, and updates from ProFound and hC
BioCentury | Sep 8, 2023
Deals
Sept. 8 Quick Takes: Appeals court backs physicians who prescribed ivermectin
Plus: Shanghai TIL play Grit closes $60M B round and deals by Alexion-Verge, Shape-Otsuka and more
Items per page:
1 - 10 of 949